Gene therapy trial targets rare heart disease in 10 patients

NCT ID NCT06109181

Ongoing Disease control Sponsor: Lexeo Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a gene therapy called LX2020 for people with a heart condition called arrhythmogenic cardiomyopathy, caused by a change in the PKP2 gene. The study involves 10 adults who already have a defibrillator implanted. The main goal is to see if the treatment is safe and tolerable.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARRHYTHMOGENIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

arrhythmogenic right ventricular cardiomyopathy arrhythmogenic right ventricular dysplasia 9 cardiac arrest cardiomyopathy Death, Sudden, Cardiac

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARRHYTHMOGENIC CARDIOMYOPATHY PKP2-ACM PKP2-ARVC

Contacts and locations

Locations

Johns Hopkins University

Baltimore, Maryland, 21287, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Stanford University

Stanford, California, 94305, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Rochester

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.